文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Prognostic value of interim PET/CT in GCB and non-GCB DLBCL: comparison of the Deauville five-point scale and the ΔSUVmax method.

作者信息

Sun Na, Qiao Wenli, Wang Taisong, Xing Yan, Zhao Jinhua

机构信息

Department of Nuclear Medicine, School of Medicine, Shanghai General Hospital, Shanghai JiaoTong University, Shanghai, 200080, China.

出版信息

BMC Cancer. 2024 Dec 27;24(1):1583. doi: 10.1186/s12885-024-13360-w.


DOI:10.1186/s12885-024-13360-w
PMID:39731077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11681756/
Abstract

BACKGROUND: This study aimed to identify the prognostic value of interim F-FDG PET/CT (I-PET) for germinal center B-cell-like (GCB) and non-GCB diffuse large B-cell lymphoma (DLBCL), respectively. METHODS: Baseline F-FDG PET/CT (B-PET) and I-PET scans were performed in 112 patients with DLBCL. The prognostic value of I-PET using the Deauville five-point scale (D-5PS) criteria or percentage decrease in SUVmax (∆SUVmax) for GCB and non-GCB DLBCL were evaluated. RESULTS: A significant difference in progression-free survival (PFS) was found between GCB and non-GCB DLBCL patients (P < 0.05). Based on D-5PS criteria, I-PET was divided into positive (score > 3) and negative (score ≤ 3) subgroups. Results indicated that I-PET using D-5PS criteria was an independent predictor for PFS of GCB DLBCL (P < 0.05), but not for overall survival (OS) (P > 0.05). For non-GCB DLBCL, PFS and OS were significantly higher in I-PET negative group than I-PET positive group (P < 0.05). Receiver operating characteristic (ROC) curve analysis proved that I-PET using ΔSUVmax can also effectively predict PFS and OS of non-GCB DLBCL (P < 0.05), but not for GCB DLBCL (P > 0.05). Based on the optimal threshold found by ROC curve analysis, patients were dichotomized into ∆SUVmax high and low groups. Log-rank test and Cox regression demonstrated that the layered ∆SUVmax was predictive of PFS and OS in non-GCB DLBCL (P < 0.05). CONCLUSIONS: I-PET may have different prognostic values for GCB and non-GCB DLBCL. Thus, the pathology type of DLBCL may be considered while using I-PET as a prognostic tool in the future.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/c58b45bd3172/12885_2024_13360_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/bf0c98018852/12885_2024_13360_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/896399b09949/12885_2024_13360_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/67b1b48e5fbc/12885_2024_13360_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/c53d3f33f9b6/12885_2024_13360_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/c58b45bd3172/12885_2024_13360_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/bf0c98018852/12885_2024_13360_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/896399b09949/12885_2024_13360_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/67b1b48e5fbc/12885_2024_13360_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/c53d3f33f9b6/12885_2024_13360_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616d/11681756/c58b45bd3172/12885_2024_13360_Fig5_HTML.jpg

相似文献

[1]
Prognostic value of interim PET/CT in GCB and non-GCB DLBCL: comparison of the Deauville five-point scale and the ΔSUVmax method.

BMC Cancer. 2024-12-27

[2]
Different predictive values of interim F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma.

Ann Nucl Med. 2017-1

[3]
Prognostic analysis of interim F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy.

Eur J Nucl Med Mol Imaging. 2018-10-31

[4]
Metabolic tumour area: a novel prognostic indicator based on F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era.

BMC Cancer. 2024-7-25

[5]
Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.

Cancer Med. 2019-7-10

[6]
Value of F-FDG PET/CT for prognostic stratification in patients with primary intestinal diffuse large B cell lymphoma treated with an R-CHOP-like regimen.

Ann Nucl Med. 2020-12

[7]
[Values of Different Evaluation Criteria of Interim F-FDG PET/CT Scan for Prediction of Prognosis in Patients with DLBCL].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017-4

[8]
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

Leuk Lymphoma. 2015-7

[9]
Prognostic Value of F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen.

J Nucl Med. 2023-4

[10]
Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.

Medicine (Baltimore). 2016-2

引用本文的文献

[1]
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Blood Adv. 2025-5-13

本文引用的文献

[1]
Evaluation of therapeutic effect and prognostic value of F-FDG PET/CT in different treatment nodes of DLBCL patients.

EJNMMI Res. 2024-2-19

[2]
Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.

J Nucl Med. 2023-11

[3]
uRP: An integrated research platform for one-stop analysis of medical images.

Front Radiol. 2023-4-18

[4]
Diffuse Large B-Cell Lymphoma and Related Entities.

Dtsch Arztebl Int. 2023-4-28

[5]
Cancer statistics, 2023.

CA Cancer J Clin. 2023-1

[6]
Prognostic Value of F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen.

J Nucl Med. 2023-4

[7]
PET/CT in Non-Hodgkin Lymphoma: An Update.

Semin Nucl Med. 2023-5

[8]
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.

Blood Adv. 2023-4-11

[9]
Treatment strategies for patients with diffuse large B-cell lymphoma.

Cancer Treat Rev. 2022-11

[10]
The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.

Eur J Nucl Med Mol Imaging. 2022-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索